Aurinia Pharmaceuticals Inc (AUPH)

[anfla]

LN IP is 2037 but the compound itself is only 2027. So if you add transplant the generics can get a transplant label in 2027 and sell for LN indirectly.

LN should be a big enough indication to grow the company. You wouldn’t add any bolt on a until you really hit cash flow positive. So either you sell the whole thing in next 24 months or weventually use the cash to grow.